Skip to main content

Advertisement

Table 2 Demographic and clinical characteristics of early and advanced-stages NSCLC patients in TCGA database cohort

From: miR-7 methylation as a biomarker to predict poor survival in early-stage non-small cell lung cancer patients

  N = 914 Methylated Unmethylated p-value
TCGA cohort: early-stage  
Sex
 Female 372 295 (79%) 77 (21%) < 0.01
 Male 542 307 (57%) 235 (43%)
Smoking status
 Current smoker 809 510 (63%) 299 (37%) < 0.01
 Never smoker 83 77 (93%) 6 (7%)
 n.a. 22   
Tumor histologic type
 Adenocarcinoma 446 423 (95%) 23 (5%) < 0.01
 Squamous 468 179 (38%) 289 (62%)
Stage
 IA 221 156 (71%) 65 (29%) < 0.045
 IB 278 187 (67%) 91 (33%)
 IIA 113 63 (56%) 50 (44%)
 IIB 160 98 (61%) 62 (39%)
 IIIA 130 90 (69%) 40 (31%)
 n.a. 12   
  N = 55 Methylated Unmethylated p-value
TCGA cohort: advanced-stage
Sex
 Female 17 15 (88%) 2 (12%) 0.12
 Male 38 26 (68%) 12 (32%)
Smoking status
 Current smoker 45 32 (70%) 13 (30%) 0.10
 Never smoker 7 0 (0%) 7 (100%)
 n.a. 3   
Tumor histologic type
 Adenocarcinoma 29 27 (93%) 2 (7%) 0.01
 Squamous 26 14 (54%) 12 (46%)
Stage
 IIIB 26 17 (65%) 9 (35%) 0.14
 IV 29 24 (83%) 5 (17%)
  1. MiR-7 methylation related to gender, smoking status, tumor histologic type, stage and RECIST
  2. n.a. result not available in TCGA cohort